Skip to main content
. 2024 Aug 9;11(40):2403177. doi: 10.1002/advs.202403177

Figure 8.

Figure 8

PRMT6 inhibitor (EPZ020411) treatment protects against OVX‐induced osteoporosis and osteoclastogenesis in vivo. A) Micro‐CT images of femurs from Sham, OVX, and OVX mice treated with EPZ020411 at low (LD) or high dose (HD) demonstrate that EPZ treatment significantly mitigates OVX‐induced trabecular bone loss, while its impact on cortical bone remains minimal. B) Micro‐CT derived parameters, including bone mineral density (BMD), bone volume fraction (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), and cortical thickness (Ct. Th) for Sham, OVX, and OVX + EPZ treated groups. C) Hematoxylin and eosin (HE) and tartrate‐resistant acid phosphatase (TRAP) stained sections of distal femurs. Upper panels: HE staining reveals the attenuation of OVX‐induced trabecular bone loss following EPZ treatment; Lower panels: TRAP staining, with red arrows highlighting TRAP+ osteoclasts, demonstrates a decrease in OVX‐induced osteoclast formation as a result of EPZ intervention. D) Quantitative analyses of osteoblast number per bone perimeter (Ob.N/B.Pm) and osteoblast surface area per bone surface area (Ob.S/BS) in distal femurs across all groups. E) Quantitative analyses of osteoclast number per bone perimeter (Oc.N/B.Pm) and osteoclast surface area per bone surface area (Oc.S/BS) in distal femurs across all groups. F) The serum level of C‐terminal telopeptide type 1 collagen (CTX‐1) was measured by ELISA assay for each group.